Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
The Centre for Ageing Better said data analysed on its behalf suggested more than a fifth of people in this age group are living in a poor-quality home that could be making their existing health condition worse. It said people from black and minority ethnic backgrounds, those living in London and those who have a serious health condition or disability are more likely to be affected. Data from the English Longitudinal Study of Ageing covering 2022/23 was analysed by the National Centre for Social Research on behalf of the charity. It found an estimated 4.5 million people aged 50 or older in England with a health condition aggravated by the cold are living in a home with one or more serious problems. Some 2.8 million were aged between 50 and 70, while 1.7 million were aged 70 and older. Health conditions included respiratory diseases, congestive heart failure, heart disease and lung conditions, including asthma. Housing problems identified in the research included damp, water leaks, bad condensation, electrical or plumbing problems, rot and decay. While some 2.2 million people over 50 with health and housing problems owned their home outright, the biggest proportion of people (51%) with such issues lived in rented accommodation. The charity said older renters with a health condition were up to three times more likely to have five or more issues with their home than someone in the same age group who owns their home. Those with a health condition that can be affected by poor housing who had a significant issue in their homes were most likely to live in London (52%) followed by the North East (35%) and the North West (35%), the West Midlands and the East of England (both on 28%), and the South West (27%). Almost half (46%) of people aged 50 and above from black and minority ethnic backgrounds with one of the health conditions had at least one problem with their home, which the charity said amounted to almost 500,000 people. Among white people in this age group it was just under one in three (32%). The research also suggested people from black and minority ethnic backgrounds living with a health condition were also more than twice as likely to have five or more issues with their housing compared with their white counterparts – 15% compared with 6%. Dr Carole Easton, the charity’s chief executive, said not only does the research show the difficulties faced by those living in poor housing, but it is also “very bad news” for both the economy and the NHS. She said: “Our latest research shows that our poor-quality housing crisis is putting people with health conditions in their 50s, 60s and beyond, in harm’s way. “This is obviously terrible for those individuals who live in homes that carry a very real risk of making them sick, particularly when winter comes around. “But it is also very bad news for the country. Older workers living in homes that are making their health conditions worse are going to be less likely to be able to work and help grow the economy. “Older people whose serious health conditions are made worse by their homes will require treatment, putting additional winter pressures on our health system. “All could be averted if we tackled poor-quality housing with the urgency and priority it demands.” Holly Holder, deputy director for homes at the charity, said the Government must “fix this hidden housing crisis by delivering a national strategy to tackle poor quality housing across all tenures and committing to halving the number of non-decent homes over the next decade”. She added: “No-one should have to live in a home that damages their health, yet it is the norm for far too many people in England today. “By failing to address poor-quality homes we are limiting the lives of some of the country’s poorest and most vulnerable people. “Our new analysis shows that the combination of health and house problems are most likely to impact groups of people who are already disadvantaged by multiple health and wealth inequalities.” A Government spokesperson said: “Despite the challenging inheritance faced by this Government, through our Plan for Change we’re taking action to improve housing conditions across all tenures and ensure homes are decent, safe and warm – especially for the most vulnerable. “We’re consulting on reforms to the Decent Homes Standard next year to improve the quality of social and privately rented housing, and introducing Awaab’s Law to both sectors to tackle damp, dangerous and cold conditions for all renters in England. “Our warm homes plan will also help people find ways to save money on energy bills and deliver cleaner heating, with up to 300,000 households to benefit from upgrades next year.”Manmohan Singh: technocrat who became India's accidental PM
Bihar civil service aspirants seek re-exam, face lathi-charge; FIR against Prashant Kishor
Trastuzumab rezetecan is under clinical development by and currently in Phase I for Head And Neck Cancer. According to GlobalData, Phase I drugs for Head And Neck Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Trastuzumab rezetecan overview Trastuzumab rezetecan (SHRA-1811) is under development for the treatment of HER2 expressing or mutated advanced malignant solid tumor, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), HER2-negative Advanced Breast Cancer, metastatic breast cancer, metastatic biliary cancer (BTC), advanced non-small cell lung cancer, metastatic colorectal cancer, gastric cancer, cervical cancer, recurrent ovarian cancer and endometrial cancer and adenocarcinoma of the gastroesophageal junction. It comprises of the anti-HER2 antibody trastuzumab, a cleavable linker, and the topoisomerase I inhibitor payload SHR169265. It is administered by intravenous and parenteral route. The drug candidate is an antibody drug conjugate which acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2. Jiangsu Hengrui Medicine overview (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China. For a complete picture of Trastuzumab rezetecan’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .The contest between the two captains—Rohit Sharma and Pat Cummins—has been decisively one-sided. Cummins has now dismissed Rohit on six occasions, with four of those coming in this very series. India’s Test captain, Rohit Sharma, found himself at the center of unwanted history once again as he was dismissed for just 9 runs on Day 5 of the fourth Test against Australia at the Melbourne Cricket Ground (MCG). This marks yet another disappointing performance in what has been a torrid series for the Indian opener. His early departure came off the bowling of Australian captain Pat Cummins, who now holds a unique record—having dismissed Rohit six times in Test matches, the most by any bowler against an opposition captain in the format. A Tough Road for Rohit Sharma Rohit’s struggles have been well-documented during this Border-Gavaskar Trophy series. Despite his patient start, where he faced 40 balls in a bid to anchor India’s second innings, he once again faltered under pressure. His dismissal was a result of an ambitious flick shot off Cummins, which found the edge and was brilliantly caught by Mitchell Marsh at gully. The wicket marked yet another failure for Rohit, who has struggled to convert his starts into substantial scores. The challenges for Rohit go beyond just a poor run of form. His inability to adapt to the testing conditions in Australia has been a growing concern for both fans and experts alike. With his form continuing to dip, calls for his retirement from the longest format of the game are gaining momentum. His current series average stands at a dismal 6.20, a stark contrast to the aggressive and confident opening batter India has known in him. The Cummins Factor: A Captain’s Duel The contest between the two captains—Rohit Sharma and Pat Cummins—has been decisively one-sided. Cummins has now dismissed Rohit on six occasions, with four of those coming in this very series. This statistic speaks volumes about the dominance Cummins has had over Rohit’s game in the Australian conditions. Rohit’s struggles are compounded by the fact that he has managed just 31 runs in five innings in this series, an average that ranks among the lowest for any Indian top-order batter in an away series. The Indian captain’s poor run also contrasts sharply with the form he displayed earlier in 2024, when he scored 455 runs in a high-scoring series against England. Since then, his form has seen a steep decline, raising doubts about his place in the Test team moving forward. Australia's Dominance Australia’s strong position in this Test match is a reflection of their commanding performance throughout the series. On Day 5, they set India a challenging target of 340 runs after being bowled out for 234 in their second innings. The Australians were once in trouble at 91/6, but a resilient performance from Pat Cummins and the tailenders ensured they extended their lead. Australia’s batting depth has consistently made life difficult for the Indian bowlers, and with the series on the line, every dismissal from India seems to come under greater scrutiny. India’s star pacer Jasprit Bumrah was once again the standout performer with the ball, claiming 5 wickets for 57 runs, a performance that included trapping Nathan Lyon in the morning session to end Australia’s innings. Bumrah’s wicket haul was a significant milestone, taking him past 200 Test wickets, a remarkable achievement in his career. The Road Ahead for India With India now needing 340 runs to win, the chase looks steep. The onus will be on the remaining batsmen to stage a miracle, and India’s hopes largely rest on players like Yashasvi Jaiswal, who has shown the ability to build innings despite the mounting pressure. However, with key players like Rohit Sharma and KL Rahul failing once again, India’s prospects of securing victory in the final Test match are looking slim. The final innings of the Border-Gavaskar Trophy will go down as a pivotal moment in the career of Rohit Sharma. His inability to rise to the occasion in the face of fierce Australian bowling, particularly from Pat Cummins, has led many to question his future in Test cricket. As the series concludes, all eyes will be on whether India’s captain can regain his form and restore his reputation, or whether his time as a Test opener for India is drawing to a close. Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.
3i Group rises Friday, still underperforms market
MELBOURNE, Australia (AP) — Australia's House of Representatives passes bill banning children younger than age 16 from social media.Tyson Foods Inc. Cl A stock outperforms competitors despite losses on the dayCOOKEVILLE, Tenn. (AP) — Rodney Johnson Jr.'s 33 points led Tennessee Tech over NAIA-member Milligan 95-75 on Sunday. Johnson added five rebounds for the Golden Eagles (6-7). Kyle Layton scored 11 points and added five assists. Ray Glasgow had 10 points and went 4 of 7 from the field (2 for 4 from 3-point range). Handje Tamba finished with 18 points and 11 rebounds for the Buffs. Sam Gold added nine points and six rebounds for Milligan. Jayme Peay also put up nine points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Mors 3-4 2-3 8, Cluff 8-11 3-3 20, Garry 3-6 2-2 9, Larson 3-8 0-0 8, Sayler 1-6 2-2 5, Hadnot 3-4 1-2 7, Jackson 2-5 0-0 5, Barnhart 2-2 0-0 5, Lindsey 0-3 0-0 0, Whorton 2-3 2-2 6, Wilkinson 1-2 0-0 2. Totals 28-54 12-14 75. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs